WO2011074006A3 - Vaccine composition - Google Patents

Vaccine composition Download PDF

Info

Publication number
WO2011074006A3
WO2011074006A3 PCT/IN2010/000814 IN2010000814W WO2011074006A3 WO 2011074006 A3 WO2011074006 A3 WO 2011074006A3 IN 2010000814 W IN2010000814 W IN 2010000814W WO 2011074006 A3 WO2011074006 A3 WO 2011074006A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine composition
formulations
immunogenic
adjuvant
enable
Prior art date
Application number
PCT/IN2010/000814
Other languages
French (fr)
Other versions
WO2011074006A2 (en
WO2011074006A4 (en
Inventor
Jadhav Suresh Sakharam
Gairola Sunil Jagdishprasad
Gautam Manish Maheshkumar
Original Assignee
Serum Institute Of India Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Ltd. filed Critical Serum Institute Of India Ltd.
Priority to CN201080057152.5A priority Critical patent/CN102655879B/en
Priority to BR112012014689-0A priority patent/BR112012014689B1/en
Publication of WO2011074006A2 publication Critical patent/WO2011074006A2/en
Publication of WO2011074006A3 publication Critical patent/WO2011074006A3/en
Publication of WO2011074006A4 publication Critical patent/WO2011074006A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The instant invention provides cost effective and immunogenic IPV formulations.The said formulations contain an adjuvant that can enable 5 to 10 fold dose reduction for inactivated polio virus vaccines.
PCT/IN2010/000814 2009-12-16 2010-12-16 Vaccine composition WO2011074006A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201080057152.5A CN102655879B (en) 2009-12-16 2010-12-16 Vaccine combination
BR112012014689-0A BR112012014689B1 (en) 2009-12-16 2010-12-16 immunogenic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2911MU2009 2009-12-16
IN2911/MUM/2009 2009-12-16

Publications (3)

Publication Number Publication Date
WO2011074006A2 WO2011074006A2 (en) 2011-06-23
WO2011074006A3 true WO2011074006A3 (en) 2011-11-17
WO2011074006A4 WO2011074006A4 (en) 2012-01-05

Family

ID=44167787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000814 WO2011074006A2 (en) 2009-12-16 2010-12-16 Vaccine composition

Country Status (3)

Country Link
CN (1) CN102655879B (en)
BR (1) BR112012014689B1 (en)
WO (1) WO2011074006A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793869B2 (en) * 2014-10-07 2023-10-24 Serum Institute Of India Pvt Ltd. Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
MX2017004534A (en) * 2014-10-07 2017-10-11 Serum Institute Of India Pvt Ltd Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
CN106290886A (en) * 2016-07-28 2017-01-04 北京科兴生物制品有限公司 A kind of method of detection III type poliovirus D antigenic content
CN108387726A (en) * 2018-01-13 2018-08-10 中国医学科学院医学生物学研究所 I, II, III type D antigens of poliovirus simultaneously and rapidly differentiate, quantitative detecting method and its detection kit and application
CN108241058A (en) * 2018-01-13 2018-07-03 中国医学科学院医学生物学研究所 A kind of pre-coated detection method of III type D antigens of poliovirus and its detection kit and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20090130146A1 (en) * 2004-10-08 2009-05-21 Chiron Behring Gmbh & Co. Kg Combination vaccine
US20090208526A1 (en) * 2004-03-15 2009-08-20 Mario Contorni Combination vaccines with low dose of hib conjugate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20090208526A1 (en) * 2004-03-15 2009-08-20 Mario Contorni Combination vaccines with low dose of hib conjugate
US20090130146A1 (en) * 2004-10-08 2009-05-21 Chiron Behring Gmbh & Co. Kg Combination vaccine

Also Published As

Publication number Publication date
CN102655879B (en) 2016-03-09
BR112012014689A2 (en) 2016-04-05
CN102655879A (en) 2012-09-05
BR112012014689B1 (en) 2019-11-12
WO2011074006A2 (en) 2011-06-23
WO2011074006A4 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
IL215430A (en) Immunogenic compositions and vaccines for immunization against viruses and use thereof
MX2008009929A (en) Yeast-based vaccine for inducing an immune response.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2008028957A3 (en) Vaccine
MX2010008799A (en) Process for stabilizing an adjuvant containing vaccine composition.
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2010019262A3 (en) Polyvalent vaccine
MX2021006342A (en) Influenza virus mutants and uses therefor.
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
MX352478B (en) Norovirus capsid and rotavirus vp6 protein for use as combined vaccine.
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
MX2012000035A (en) Recombinant rsv antigens.
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2011094363A3 (en) Influenza virus compositions and methods for universal vaccines
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
WO2008054481A3 (en) Improved inactivated influenza virus compositions
MX349119B (en) Inactivated dengue virus vaccine.
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
MX2009006178A (en) Salmonella vaccine.
WO2011074006A3 (en) Vaccine composition
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
WO2010053610A3 (en) Stable anthrax vaccine formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080057152.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10837174

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10837174

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10837174

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012014689

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012014689

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120615